Artificial flavouring (multi-fruit flavour), sweeteners: sucralose (E955, 24mg/100ml), preservatives: sodium benzoate (E211), Potassium sorbate (E202)
This metabolic shift creates an opportunity to support your body with targeted micronutrients that optimize energy, bone health, and immune resilience throughout your wellness journey
Type 1 diabetes was diagnosed in 19 (43%) of participants who received teplizumab and 23 (72%) of those who received placebo (hazard ratio [HR] 0.41
Sustainable weight loss depends not only on medication, but also on addressing underlying metabolic drivers, as outlined in A Functional Medicine Approach to Weight Loss
For diabetes management, the eligibility criteria included a diabetes diagnosis, a hemoglobin A1c (HbA1c) level of at least 7.0%, or current use of diabetes therapies